Qiagen NV (QGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qiagen NV (QGEN) has a cash flow conversion efficiency ratio of 0.050x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($188.13 Million) by net assets ($3.78 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Qiagen NV - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Qiagen NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read QGEN total liabilities for a breakdown of total debt and financial obligations.
Qiagen NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qiagen NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Astor Enerji AS
IS:ASTOR
|
0.068x |
|
Volvo Car AB (publ.)
ST:VOLCAR-B
|
0.019x |
|
ALPHA SE+H.ADR1/4/EO 390
F:ACBC
|
-0.040x |
|
The Phoenix Mills Limited
NSE:PHOENIXLTD
|
0.084x |
|
Yunnan Copper Co Ltd
SHE:000878
|
0.068x |
|
Voya Financial Inc
NYSE:VOYA
|
0.024x |
|
Schaeffler India Limited
NSE:SCHAEFFLER
|
0.131x |
|
Hyatt Hotels Corporation
NYSE:H
|
0.096x |
Annual Cash Flow Conversion Efficiency for Qiagen NV (1995–2025)
The table below shows the annual cash flow conversion efficiency of Qiagen NV from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Qiagen NV.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.78 Billion | $654.33 Million | 0.173x | -8.27% |
| 2024-12-31 | $3.57 Billion | $673.55 Million | 0.189x | +56.48% |
| 2023-12-31 | $3.81 Billion | $459.45 Million | 0.121x | -41.52% |
| 2022-12-31 | $3.47 Billion | $715.26 Million | 0.206x | -0.01% |
| 2021-12-31 | $3.10 Billion | $639.00 Million | 0.206x | +17.28% |
| 2020-12-31 | $2.80 Billion | $492.27 Million | 0.176x | +34.90% |
| 2019-12-31 | $2.54 Billion | $330.84 Million | 0.130x | -4.40% |
| 2018-12-31 | $2.63 Billion | $359.50 Million | 0.136x | +20.89% |
| 2017-12-31 | $2.54 Billion | $286.78 Million | 0.113x | -13.86% |
| 2016-12-31 | $2.61 Billion | $341.60 Million | 0.131x | +5.73% |
| 2015-12-31 | $2.56 Billion | $317.50 Million | 0.124x | +14.39% |
| 2014-12-31 | $2.66 Billion | $287.96 Million | 0.108x | +13.96% |
| 2013-12-31 | $2.72 Billion | $258.96 Million | 0.095x | +5.77% |
| 2012-12-31 | $2.72 Billion | $244.88 Million | 0.090x | -6.08% |
| 2011-12-31 | $2.56 Billion | $244.78 Million | 0.096x | -5.49% |
| 2010-12-31 | $2.48 Billion | $250.75 Million | 0.101x | +6.92% |
| 2009-12-31 | $2.29 Billion | $217.00 Million | 0.095x | -20.41% |
| 2008-12-31 | $1.45 Billion | $173.00 Million | 0.119x | +95.32% |
| 2007-12-31 | $1.39 Billion | $84.81 Million | 0.061x | -66.01% |
| 2006-12-31 | $566.16 Million | $101.48 Million | 0.179x | -11.51% |
| 2005-12-31 | $450.46 Million | $91.24 Million | 0.203x | +50.74% |
| 2004-12-31 | $400.38 Million | $53.80 Million | 0.134x | -29.78% |
| 2003-12-31 | $334.79 Million | $64.06 Million | 0.191x | +37.19% |
| 2002-12-31 | $263.03 Million | $36.69 Million | 0.139x | -48.86% |
| 2001-12-31 | $212.97 Million | $58.09 Million | 0.273x | +15.47% |
| 2000-12-31 | $164.58 Million | $38.87 Million | 0.236x | -16.39% |
| 1999-12-31 | $92.66 Million | $26.18 Million | 0.282x | +78.02% |
| 1998-12-31 | $73.10 Million | $11.60 Million | 0.159x | +0.81% |
| 1997-12-31 | $54.00 Million | $8.50 Million | 0.157x | +83.13% |
| 1996-12-31 | $47.70 Million | $4.10 Million | 0.086x | -73.11% |
| 1995-12-31 | $12.20 Million | $3.90 Million | 0.320x | -- |
About Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technol… Read more